|
CHD4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64535052249448E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.15223411209809E-13 |
| Normal-vs-Stage2 |
1.87757999999816E-05 |
| Normal-vs-Stage3 |
4.39299996379816E-09 |
| Normal-vs-Stage4 |
1.93269955595099E-10 |
| Stage1-vs-Stage2 |
7.530000E-01 |
| Stage1-vs-Stage3 |
3.719600E-01 |
| Stage1-vs-Stage4 |
5.027600E-01 |
| Stage2-vs-Stage3 |
4.279000E-01 |
| Stage2-vs-Stage4 |
8.851200E-01 |
| Stage3-vs-Stage4 |
2.083600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.61932706027801E-14 |
| Normal-vs-AfricanAmerican |
1.61598999999235E-05 |
| Normal-vs-Asian |
1.20780000001375E-07 |
| Caucasian-vs-AfricanAmerican |
9.872300E-02 |
| Caucasian-vs-Asian |
8.892600E-01 |
| AfricanAmerican-vs-Asian |
1.081240E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.97130001211576E-09 |
| Normal-vs-Female |
8.99280649946377E-15 |
| Male-vs-Female |
1.336560E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.02573505245118E-12 |
| Normal-vs-Age(41-60Yrs) |
8.82005579683209E-12 |
| Normal-vs-Age(61-80Yrs) |
2.80149999865031E-08 |
| Normal-vs-Age(81-100Yrs) |
8.437500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.185600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.080400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.375190E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.082400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.988400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.918400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.665370E-01 |
| Classical-VS-Follicular |
4.25680000137874E-08 |
| Classical-VS-Other |
3.238100E-02 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
4.740200E-02 |
| Tall-VS-Other |
1.185170E-01 |
| Tall-VS-Normal |
1.20900000000201E-06 |
| Follicular-VS-Other |
7.602000E-01 |
| Follicular-VS-Normal |
1.045770E-02 |
| Other-VS-Normal |
5.271600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.65219981929488E-10 |
| Normal-vs-N1 |
4.94979999998701E-06 |
| N0-vs-N1 |
8.245800E-01 |
|
|
